CorMedix develops and sells DefenCath, a catheter lock solution for dialysis patients, plus hospital infection drugs and a heart medicine. CRMD reports earnings on Wed, Nov 11, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 23 | Oppenheimer | Initiated | Buy |
Seasonality
How CRMD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.
Whale Options Flow
90DNo whale options trades in CRMD in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRMD is in one of them and how their past CRMD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CRMD in an article yet. Here's the latest on the wider market.
About CorMedix
CorMedix is a biopharmaceutical company based in Parsippany, New Jersey, that develops and sells drugs for serious medical conditions. Its main product is DefenCath, a catheter lock solution that helps reduce bloodstream infections in adult kidney failure patients who receive dialysis through a central venous catheter. Its customers are mainly outpatient dialysis clinics and hospitals. The company also sells a set of hospital-focused drugs for serious infections, including REZZAYO and VABOMERE, along with the heart drug TOPROL XL. These products are used in hospitals, emergency departments, outpatient clinics and home infusion care.
- Headquarters
- Parsippany, NJ